Federated Hermes, Inc. Intra Cellular Therapies, Inc. Transaction History

Federated Hermes, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$52.09 - $64.1 $457,298 - $562,733	8,779 New	8,779 $457,000
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $817 - $1,247	19 New	19 $1,000
Q4 2020 Feb 12, 2021	SELL	$23.34 - $32.22 $12,276 - $16,947	-526 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$17.61 - $31.86 $1.19 Million - $2.16 Million	-67,833 Reduced 99.23%	526 $13,000
Q2 2020 Aug 13, 2020	BUY	$14.35 - $26.64 $357,401 - $663,495	24,906 Added 57.32%	68,359 $1.76 Million
Q1 2020 May 13, 2020	BUY	$12.31 - $33.12 $297,865 - $801,404	24,197 Added 125.66%	43,453 $668,000
Q4 2019 Feb 14, 2020	BUY	$7.26 - $38.49 $139,798 - $741,163	19,256 New	19,256 $661,000
Q3 2018 Nov 13, 2018	SELL	$17.77 - $22.9 $479 - $618	-27 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$17.33 - $23.4 $1.55 Million - $2.1 Million	-89,716 Reduced 99.97%	27 $1,000
Q1 2018 May 09, 2018	SELL	$15.16 - $25.49 $1.01 Million - $1.7 Million	-66,842 Reduced 42.69%	89,743 $1.89 Million
Q4 2017 Feb 14, 2018	BUY	$14.27 - $16.79 $13,784 - $16,219	966 Added 0.62%	156,585 $0
Q3 2017 Nov 13, 2017	BUY	$10.77 - $22.1 $1.68 Million - $3.44 Million	155,619	155,619 $2.46 Million

381

84M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.